Shanghai RAAS(SZ:002252) Shang Hai Zheng Quan Bao·2025-10-31 19:31Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. announced the completion of a share buyback plan by certain directors and senior management, reflecting their confidence in the company's strategic development and long-term investment value [3][10]. Summary by Sections Share Buyback Plan - The company disclosed a plan for certain directors and senior management to increase their shareholdings starting from September 5, 2025, for a period of six months, with a minimum investment of RMB 6 million [3][10]. - The buyback was executed through centralized bidding, resulting in the acquisition of 946,000 shares, representing 0.014% of the total share capital, with a total expenditure of RMB 6.4828 million [10]. Participants in the Buyback - The buyback involved key executives including Jun Xu, Shen Jihui, Lu Hui, Liu Zheng, Song Zhengmin, Chen Leqi, and Huang Qinbing [3][10]. - Prior to the buyback, these executives held shares under the first employee stock ownership plan, with specific unblocked shares awaiting conditions for release [4]. Purpose and Conditions - The buyback aims to enhance investor confidence and is based on the executives' strong belief in the company's strategic direction [6][10]. - There is no set price range for the buyback; the executives will determine the timing based on their assessment of the stock's value [6][10]. Compliance and Regulations - The buyback adheres to relevant laws and regulations, ensuring that it does not affect the company's share distribution or control [10]. - The participating executives committed to not selling their shares during the lock-up period following the buyback [9][10].